AstraZeneca
AZN
1,061 hedge funds and large institutions have $34.1B invested in AstraZeneca in 2022 Q4 according to their latest regulatory filings, with 171 funds opening new positions, 313 increasing their positions, 358 reducing their positions, and 50 closing their positions.
242% more first-time investments, than exits
New positions opened: 171 | Existing positions closed: 50
27% more funds holding in top 10
Funds holding in top 10: 15 → 19 (+4)
21% more capital invested
Capital invested by funds: $28.3B → $34.1B (+$5.82B)
10% more funds holding
Funds holding: 965 → 1,061 (+96)
0% less call options, than puts
Call options by funds: $468M | Put options by funds: $469M
0.26% less ownership
Funds ownership: 16.64% → 16.38% (-0.26%)
13% less repeat investments, than reductions
Existing positions increased: 313 | Existing positions reduced: 358
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$238M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$235M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$148M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$140M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$99.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$426M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$280M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$234M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$205M |
| 5 |
Renaissance Technologies
New York
|
-$137M |
AZN Hedge Fund Activity: Q4 2022 in Review
1,061 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2022, worth a combined $34.1B — up 21% from $28.3B a quarter earlier.
Buyers outnumbered sellers: 171 funds opened new AZN positions and 50 closed out — a net gain of 121 holders — while 313 added to existing stakes and 358 trimmed.
The largest buyer was Capital World Investors, adding an estimated $238M. The largest seller was T. Rowe Price Associates, cutting an estimated $426M.
- 1,061 institutional investors held AstraZeneca (AZN) as of Q4 2022, up from 965 in Q3 2022.
- Funds reported $34.1B of AstraZeneca stock for Q4 2022, up 21% quarter-over-quarter.
- 171 funds opened new AstraZeneca positions in Q4 2022 and 50 closed out, a net change of +121 holders.
- The largest AstraZeneca buyer in Q4 2022 was Capital World Investors, an estimated $238M added.
- The largest AstraZeneca seller in Q4 2022 was T. Rowe Price Associates, an estimated $426M sold.
Based on aggregated 13F filings for Q4 2022.